Allianz close to an agreement for the acquisition of European Reliance
Παρασκευή 11 Φεβρουαρίου 2022
European Reliance 52 week high
Πέμπτη 10 Φεβρουαρίου 2022
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049) - NET DEBT
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049) - NET DEBT
Τετάρτη 9 Φεβρουαρίου 2022
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049) - Revenue
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049) - Revenue
Κυριακή 6 Φεβρουαρίου 2022
Σάββατο 5 Φεβρουαρίου 2022
MYTILINEOS S.A. (MYTIL:ATH) ΤΟΤΑL DEBT VS TOTAL CASH €
MYTILINEOS S.A. (MYTIL:ATH) ΤΟΤΑL DEBT VS TOTAL CASH €
Παρασκευή 4 Φεβρουαρίου 2022
Bayer will discontinue phase II development candidate eliapixant
Bayer will discontinue phase II development candidate eliapixantReview of development program led to reassessment of benefit-risk ratio in all four potential indications for the investigational P2X3 receptor antagonist
Berlin, Germany, February 4, 2022 – Bayer today announced the discontinuation of Phase II development candidate eliapixant (BAY 1817080), an investigational P2X3 receptor antagonist that was being evaluated for potential indications in endometriosis, refractory chronic cough, overactive bladder and diabetic neuropathic pain. Following a review of available data, Bayer concluded that the overall benefit no longer outweighs the risk in these indications.
Eliapixant is an investigational agent and has not been approved for use in any country, for any indication.
Πέμπτη 3 Φεβρουαρίου 2022
Τετάρτη 2 Φεβρουαρίου 2022
Εγγραφή σε:
Αναρτήσεις (Atom)